Binding of various EHEC LPS serotypes to platelets
LPS and concentration . | Median LPS binding, % (range) . | P . |
|---|---|---|
| O157:H7* | ||
| Untreated | 0.2 (0.0-0.9) | |
| 100 ng/mL | 1.4 (0.2-3.9) | <.001 |
| 1 μg/mL | 62.3 (22.6-92.9) | <.001 |
| O103:H2†‡ | ||
| Untreated | 0.9 (0.1-1.9) | |
| 100 ng/mL | 0.9 (0.0-2.0) | .739# |
| 1 μg/mL | 8.5 (3.3-25.0) | <.001 |
| O111:HNठ| ||
| Untreated | 1.3 (1.0-2.0) | |
| 100 ng/mL | 1.4 (1.1-2.0) | >.999# |
| 1 μg/mL | 11.9 (6.2-12.7) | <.001 |
| O121:H19‡∥ | ||
| Untreated | 1.0 (0.7-1.9) | |
| 100 ng/mL | 1.3 (1.0-2.4) | .603# |
| 1 μg/mL | 9.7 (1.3-18.0) | <.001 |
| O111:B4¶ | ||
| Untreated | 0.4 (0.0-0.7) | |
| 100 ng/mL | 0.5 (0.1-0.9) | .827# |
| 1 μg/mL | 9.2 (6.7-22.5) | .008 |
LPS and concentration . | Median LPS binding, % (range) . | P . |
|---|---|---|
| O157:H7* | ||
| Untreated | 0.2 (0.0-0.9) | |
| 100 ng/mL | 1.4 (0.2-3.9) | <.001 |
| 1 μg/mL | 62.3 (22.6-92.9) | <.001 |
| O103:H2†‡ | ||
| Untreated | 0.9 (0.1-1.9) | |
| 100 ng/mL | 0.9 (0.0-2.0) | .739# |
| 1 μg/mL | 8.5 (3.3-25.0) | <.001 |
| O111:HNठ| ||
| Untreated | 1.3 (1.0-2.0) | |
| 100 ng/mL | 1.4 (1.1-2.0) | >.999# |
| 1 μg/mL | 11.9 (6.2-12.7) | <.001 |
| O121:H19‡∥ | ||
| Untreated | 1.0 (0.7-1.9) | |
| 100 ng/mL | 1.3 (1.0-2.4) | .603# |
| 1 μg/mL | 9.7 (1.3-18.0) | <.001 |
| O111:B4¶ | ||
| Untreated | 0.4 (0.0-0.7) | |
| 100 ng/mL | 0.5 (0.1-0.9) | .827# |
| 1 μg/mL | 9.2 (6.7-22.5) | .008 |
Platelets were exposed to EHEC LPS or non-EHEC LPS (O111:B4) ex vivo, and percentage binding of the total population was determined by flow cytometry. P values were based on comparisons of LPS-treated platelets with untreated platelets.
Median value from 23 experiments.
Median value from 10 experiments.
EHEC LPS-serotypes were isolated from patients in whom HUS did not develop.
Median value from 11 experiments.
Median value from 14 experiments.
Median value from 5 experiments.
Not significant.